Melissa A Breitling, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3102 Goodman Rd W, Horn Lake, MS 38637 Phone: 662-342-6677 Fax: 662-393-8819 |
News Archive
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 second quarter, ended December 31, 2009.
Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.
Companies invest hundreds of millions – and occasionally billions – of dollars overall in developing new drugs and face countless hurdles in bringing these new products to market. To make good on these vast investments, successful companies must maximize product uptake across all customer groups: not only among patients and physicians, but also among government and private payers to win formulary access and improve product placement.
Scientists have conducted a systematic review of published studies investigating the duration of efficacy of COVID-19 vaccines against SARS-CoV-2 infection and disease severity.
Research efforts associating scientists from the CNRS, UVSQ and INSERM within the Laboratoire END-ICAP, working in collaboration with a team from the University of Bern, has demonstrated the therapeutic potential of a new class of synthetic oligonucleotides in the treatment of Duchenne muscular dystrophy (DMD) using RNA "surgery".
› Verified 9 days ago